This document contains a series of case reports describing the use of ACTISORB® (Systagenix) in patients with a range of wound types. All patients were treated for a minimum of 2–4 weeks and the decision to continue with ACTISORB® was based on continual assessment. A formal assessment was performed weekly, although in some cases dressing changes were carried out more frequently.
Supported by Systagenix – An Acelity Company
For the latest news and articles
© Copyright Omniamed Communications. All Rights Reserved
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom
Free for all healthcare professionals
By clicking ‘Subscribe’, you are agreeing that the Wounds Group are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our privacy policy.
Are you a healthcare professional? This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.
We use cookies responsibly to ensure that we give you the best experience on our website. If you continue without changing your browser settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies.
